Home/Pipeline/Topical PSGAG

Topical PSGAG

Osteoarthritis

Pre-clinicalActive

Key Facts

Indication

Osteoarthritis

Phase

Pre-clinical

Status

Active

Company

ADORA Life Science

About ADORA Life Science

ADORA Life Science is a private, preclinical-stage biotech founded in 2018, pioneering a novel polysulfated glycosaminoglycan (PSGAG) platform for osteoarthritis. The company is targeting an $8B+ global osteoarthritis market with a potential first-in-class topical DMOAD, backed by strong IP protection extending to 2043. Led by an experienced team with prior successful exits, ADORA is advancing its lead program toward human clinical development while leveraging existing veterinary use data.

View full company profile

Therapeutic Areas

Osteoarthritis Inflammatory Pain

Other Osteoarthritis Drugs

Drug	Company	Phase	Status
MSC‑OA	Advancells	Phase 1	Active
Osteoarthritis program	Risen Pharma Tech	Clinical (China & US)	Active
ViscoCell™ for Osteoarthritis	Likarda	Pre-clinical	Active
Osteoarthritis Biologic Therapy	Ageless Biotech	Phase 2b	Active
PKM-011	PK MED	Pre-clinical	Active
CYT-108	Cytonics	Phase 2	Active
FGF18 Gene Therapy	Remedium Bio	Pre-clinical	Active
MOTYS™	Doron Therapeutics	Phase 3	Active
Osteoarthritis Treatment Program	Biovico	Pre-clinical	Active
aGF	Scarcell Therapeutics	Phase 1	Active
Cartilage Repair	Sayenza Biosciences	Clinical	Active
BRM521	BRIM Biotechnology	Preclinical	Active